Aarti Drugs Q3 PAT Surges 58%, But EBITDA Margins Contract

CHEMICALS
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Aarti Drugs Q3 PAT Surges 58%, But EBITDA Margins Contract
Overview

Aarti Drugs posted a robust 58% YoY jump in Q3 FY26 net profit to ₹40.5 crore, driven by an 8% revenue increase to ₹602.9 crore. However, operating profitability faced pressure, with EBITDA declining 10% YoY to ₹56.3 crore and margins compressing by 190 basis points to 9.3%, attributed to inventory costs and maintenance. A significant IT tax refund boosted net profit. Management expects margin recovery and volume uptick from new capacities.

📉 The Financial Deep Dive

The Numbers: Aarti Drugs Limited announced its Q3 FY26 financial results, revealing a mixed performance. Total revenue climbed 8% year-on-year to ₹602.9 crore. Profit After Tax (PAT) witnessed a significant surge of 58% YoY to ₹40.5 crore, translating to an Earnings Per Share (EPS) of ₹4.44. Conversely, Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) contracted by 10% YoY to ₹56.3 crore. EBITDA margins consequently narrowed by 190 basis points to 9.3%.

The nine-month period (9M FY26) showed a more stable trend, with revenue growing 8% YoY to ₹1,846.6 crore and PAT increasing by 49% YoY to ₹139.7 crore. 9M EBITDA was up 9% YoY at ₹215.0 crore, with margins largely flat at 11.6%.

The Quality: The substantial PAT growth was aided by an IT tax refund of ₹16.38 crore during the quarter. The margin compression in Q3 FY26 was attributed to several factors including the consumption of higher-cost inventory, temporary plant shutdowns for scheduled maintenance, and raw material shipment issues causing shortages and reliance on older stock. While the quarterly EBITDA declined, the 9M EBITDA showed healthy growth and stable margins, suggesting the quarterly dip might be temporary.

The Grill: Management acknowledged the margin pressure in Q3, linking it primarily to inventory costs from the previous year and operational adjustments. The company's focus is on overcoming these headwinds through operational efficiency and capacity ramp-up. The outlook points towards stable prices and an anticipated uptick in volume momentum. Key growth drivers include the backward integration plant for methyl amines (at 30% capacity utilization, targeting 50% by March/April 2026), achieving self-reliance for Metformin intermediate within 6-8 months, and scaling up the Salicylic Acid plant and its downstream Salicylates line.

🚩 Risks & Outlook

Specific Risks: The primary risk lies in the successful and timely execution of capacity expansions and backward integration projects. Margin recovery will be critical; any sustained pressure could impact profitability. Dependence on specific intermediates and global regulatory approvals also presents ongoing risks.

The Forward View: Investors will be watching for margin recovery in the subsequent quarters as higher-cost inventory is consumed and new capacities become more efficient. The company's ability to manage raw material costs and secure necessary regulatory approvals for exports will be crucial. The ongoing Capex of approximately ₹600 crore, aimed at boosting capacity and margins, signifies a commitment to future growth. Progress on the captive solar power plants also points towards cost control initiatives.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.